| Clinical implications of difference in antigenicity of different botulinum neurotoxin type A preparations: clinical take-home messages from our research pool and literature S Samadzadeh, B Ürer, R Brauns, D Rosenthal, JI Lee, P Albrecht, ... Toxins 12 (8), 499, 2020 | 24 | 2020 |
| Relationship between HLA-DRB1* 11/15 genotype and susceptibility to multiple sclerosis in Iran R Abolfazli, S Samadzadeh, T Sabokbar, B Siroos, SA Armaki, ... Journal of the neurological sciences 345 (1-2), 92-96, 2014 | 19 | 2014 |
| Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 HY Wunrow, RG Bender, A Vongpradith, SB Sirota, LR Swetschinski, ... The Lancet Neurology 22 (8), 685-711, 2023 | 18 | 2023 |
| Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the … AE Schumacher, HH Kyu, A Aali, C Abbafati, J Abbas, ... The Lancet, 2024 | 14 | 2024 |
| Disease progression of idiopathic cervical dystonia in spite of improvement after botulinum toxin therapy H Hefter, I Schomaecker, M Schomaecker, S Samadzadeh Frontiers in Neurology 11, 588395, 2020 | 14 | 2020 |
| Omalizumab prevents anaphylactoid reactions to mRNA COVID‐19 vaccine A Smola, S Samadzadeh, L Müller, O Adams, B Homey, P Albrecht, ... Journal of the European Academy of Dermatology and Venereology 35 (11), e743, 2021 | 13 | 2021 |
| Long‐term adherence and response to botulinum toxin in different indications JI Lee, A Jansen, S Samadzadeh, U Kahlen, M Moll, M Ringelstein, ... Annals of Clinical and Translational Neurology 8 (1), 15-28, 2021 | 13 | 2021 |
| Clinical improvement after treatment with incobotulinumtoxinA (XEOMIN®) in patients with cervical dystonia resistant to botulinum toxin preparations containing complexing proteins H Hefter, CJ Hartmann, U Kahlen, S Samadzadeh, D Rosenthal, M Moll Frontiers in Neurology 12, 636590, 2021 | 12 | 2021 |
| Global, regional, and national burden of spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 M Safdarian, E Trinka, V Rahimi-Movaghar, A Thomschewski, A Aali, ... The Lancet Neurology 22 (11), 1026-1047, 2023 | 11 | 2023 |
| Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 JD Steinmetz, KM Seeher, N Schiess, E Nichols, B Cao, C Servili, ... The Lancet Neurology 23 (4), 344-381, 2024 | 10 | 2024 |
| Significantly lower antigenicity of incobotulinumtoxin than abo-or onabotulinumtoxin H Hefter, D Rosenthal, A Jansen, R Brauns, B Ürer, H Bigalke, ... Journal of Neurology 270 (2), 788-796, 2023 | 10 | 2023 |
| HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients S Samadzadeh, E Tabibian, T Sabokbar, A Shakoori, SR Dehgolan, ... Journal of the Neurological Sciences 352 (1-2), 37-40, 2015 | 10 | 2015 |
| The impact of SARS-CoV-2 pandemic lockdown on a botulinum toxin outpatient clinic in Germany S Samadzadeh, R Brauns, D Rosenthal, H Hefter Toxins 13 (2), 101, 2021 | 9 | 2021 |
| The impact of the initial severity on later outcome: Retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia H Hefter, S Samadzazeh, D Rosenthal Journal of Neurology 268, 206-213, 2021 | 9 | 2021 |
| Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019 GBDI Collaborators EClinicalMedicine, 2023 | 7 | 2023 |
| The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease … GBDCACD Collaborators The Lancet 402 (10398), 313-335, 2023 | 6 | 2023 |
| The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis S Asseyer, N Asgari, J Bennett, O Bialer, Y Blanco, F Bosello, ... Frontiers in Neurology 14, 1102353, 2023 | 6 | 2023 |
| Effective treatment of neurological symptoms with normal doses of botulinum neurotoxin in Wilson’s disease: six cases and literature review H Hefter, S Samadzadeh Toxins 13 (4), 241, 2021 | 6 | 2021 |
| Pseudocholinesterase as a Biomarker for Untreated Wilson’s Disease H Hefter, M Arslan, TS Kruschel, M Novak, D Rosenthal, SG Meuth, ... Biomolecules 12 (12), 1791, 2022 | 5 | 2022 |
| Significant long-lasting improvement after switch to incobotulinum toxin in cervical dystonia patients with secondary treatment failure H Hefter, B Ürer, R Brauns, D Rosenthal, SG Meuth, JI Lee, P Albrecht, ... Toxins 14 (1), 44, 2022 | 5 | 2022 |
Philipp AlbrechtProfessor of NeurologyBestätigte E-Mail-Adresse bei mariahilf.de
